Catalyst Pharmaceuticals Inc. stock underperforms Friday when compared to competitors
Catalyst Pharmaceuticals Inc. closed $2.35 short of its 52-week high ($24.27), which the company reached on November 8th.
Catalyst Pharmaceuticals price target raised to $31 from $29 at Oppenheimer
Oppenheimer raised the firm’s price target on Catalyst Pharmaceuticals (CPRX) to $31 from $29 and keeps an Outperform rating on the shares.
Catalyst Pharmaceuticals price target raised to $35 from $30 at H.C. Wainwright
H.C. Wainwright analyst Andrew Fein raised the firm’s price target on Catalyst Pharmaceuticals (CPRX) to $35 from $30 and keeps a Buy rating on ...
New device harnesses microwave flow reaction to convert biomass into useful sugars
Researchers at Kyushu University have developed a device that combines a catalyst and microwave flow reaction to efficiently ...
Hippocratic AI secures $141m in Series B funding
Healthcare-focused AI startup Hippocratic AI has closed its Series B financing round, raising $141m, led by venture capital ...
Investor's Business Daily on MSN18h
Stocks Generating Improved Relative Strength: Alnylam Pharmaceuticals
Alnylam Pharmaceuticals shows rising price performance, earning an upgrade to its IBD Relative Strength Rating ...
Investor's Business Daily on MSN18h
Alkermes Shows Rising Relative Price Performance; Still Shy Of Key Benchmark
Rating on Friday, rising from 69 to 74. Please watch the video at Investors.com - How To Find Game-Changing Stocks This proprietary rating tracks technical performance by showing how a stock's price ...
Dow tumbles nearly 700 points Friday as strong jobs report casts doubt over Fed's rate-cut path
The Dow Jones Industrial Average lost 696.75 points, or 1.63%, to close at 41,938.45. The S&P 500 slid 1.54% to 5,827.04, ...
Ghana Business News1h
Ghana government urged to prioritise salt development to grow economy
Professor Douglas Boateng, Board Chairman of the Minerals Income Investment Fund (MIIF), has underscored the potential of ...
Crinetics falls after mid-stage trial data adrenal disorder therapy
Crinetics Pharmaceuticals (CRNX) stock fell after Phase 2 results for its experimental drug atumelnant for congenital adrenal hyperplasia. Read more here.